Recon: Illumina agrees to divest Grail after antitrust battle; Indian retailer IndiaMART working with Novo to stop illicit Wegovy sales

• Illumina says it will divest Grail, starting a closing chapter for a disastrous deal (STAT)
• Icahn aims to remove Illumina's legacy directors – letter (Reuters)
• Here are the best biopharma CEOs of 2023 (STAT)
• The biggest health care deals of 2023 (STAT)
• FDA rejects Checkpoint Therapeutics' PD-L1 drug cosibelimab over manufacturing issues (Endpoints)

• Exclusive: IndiaMART is working with Novo Nordisk to halt illegal Wegovy sales - source (Reuters)
• BioNTech aims to start mRNA vaccine output in Rwanda in 2025 (Reuters)
• ‘Two Minutes To Midnight’ For Germany’s Medtechs – Spectaris At Medica 2023 (MedTech Insight)
• Updated: Pear Therapeutics PDTs Reborn In PursueCare, Supported By Pear's Ex-CEO (MedTech Insight)
• Classification And Equivalence Guidances Published For MDR’s Non-Medical Devices (MedTech Insight)

• ‘We’ve exhausted all avenues’: A small biotech may give up on its ultra-rare disease drug over frustration with FDA (STAT)
• Structure Therapeutics GLP-1 pill cuts blood sugar, weight in early diabetes study (STAT)
• Structure's diabetes pill misses weight-loss expectations in mid-stage trial (Reuters)
• Wegovy may have another helpful trick: fighting inflammation via the brain, study finds (STAT)
• Novo owner commits $265 mln of Wegovy windfall to respiratory diseases (Reuters)
• Novo Nordisk Foundation to launch $260M vaccine initiative in early 2024 (Endpoints)
• GSK's cancer drug combination meets primary goal in late-stage trial (Reuters)
• Checkpoint Therapeutics slides after US FDA declines cancer therapy approval (Reuters)
• Point Biopharma’s closely watched prostate cancer radiopharmaceutical study disappoints, Lilly again extends offer (Endpoints)
• Covid biotech’s stock jumps after positive early PhIII monoclonal antibody data reveal (Endpoints)
• First Wave to merge with ImmunogenX; Caliway raises $100M; New deals for Replay’s Syena (Endpoints)
• Exclusive: A longtime VC takes on his own rare disease as Sanofi, Boehringer commit $80M to launch new platform study (Endpoints)
• Bristol Myers cuts PhIII PD-1/LAG-3 trial in colorectal cancer short after drug combo fails analysis (Endpoints)
• VC firm Pivotal closes second $389M therapeutics fund to create companies and back public biotechs (Endpoints)

• Zimvie to sell spine business for $375M (MedTech Dive)
• BTIG analysts optimistic medtech will rebound in 2024 after ‘string of rough years’ (MedTech Dive)
• Glaukos wins FDA approval for drug-releasing eye implant to treat glaucoma (MedTech Dive)
• Tandem completes US launch of revamped diabetes management platform (MedTech Dive)
• MTI 100: Global Medtech Recovers Core Growth After A Year Like No Other (MedTech Insight)
• News We’re Watching: Henry Schein Hack, New Codes For Shockwave And Eckso, Breast Implant Safety Update (MedTech Insight)

• The legal pathway for experimental, ultra-rare disease treatments is rocky and expensive (STAT)
• Alzheimer’s drug approvals show we need a reevaluation of patient advocacy (STAT)
• NIH panel calls for fewer, better-paid postdocs in bid to halt loss of scientists to industry (STAT)
• New Jersey’s telehealth restrictions cut off access to lifesaving care, lawsuit alleges (STAT)
• Governors’ Push President on Cannabis Rescheduling But Overlook What Schedule III Would Require (FDA Law Blog)